1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
The Japanese government plans to support companies shifting to around-the-clock manufacturing for the supply ramp-up of cough medicines and other symptomatic treatments for infectious diseases, Health Minister Keizo Takemi revealed on November 7. “For companies that have responded to our…
To read the full story
Related Article
- Shionogi CEO Requests Higher Price for Medicon
November 22, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Shionogi Sees 60% Ramp-Up in Medicon Output in FY2023
February 2, 2024
- Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
December 15, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
October 20, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
- JMA Survey Finds Large Gap between Actual Drug Shortage, Industry Poll
October 11, 2023
REGULATORY
- Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
- J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
- Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
- MHLW Not Yet Able to Examine Letters of Protest by US Lobbies: Minister
February 13, 2025
- Set Deadline for Non-Prescription Pilot of Morning-After Pill: Panel Members
February 13, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…